Alembic Pharmaceuticals has received USFDA approval for Carbidopa and Levodopa extended-release tablets which is used for treatment of Parkinson’s disease. The drug is therapeutically equivalent to the reference listed drug Sinemet CR tablets of Merck Sharp and Dohme. It will be made available in in the strengths of 25 mg/100 mg and 50 mg/200 mg.
According to market estimates, the Carbidopa and Levodopa extended-release tablets had an estimated market size of USD 24 million for 12 months ended December 2018.
Company Profile : Alembic Pharmaceuticals Ltd